Science

Mar 5, 2025, 10:04

Myeloma Paper of the Day, March 5th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Management of CRS related to teclistamab in patients with relapsed/refractory myeloma can be successful with as little as one dexamethasone dose of 10 mg and without compromising the response rate.”

“Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma”

Authors: James Davis, Jordan Snyder, Mikhaila Rice, Zahra Mahmoudjafari, Victoria Nachar et al.

More posts featuring Robert Orlowski.

cancer James Davis Jordan Snyder Mikhaila Rice Myeloma Paper of the Day OncoDaily Oncology relapsed/refractory myeloma Robert Orlowski RRMM Victoria Nachar Zahra Mahmoudjafari

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer